<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049061</url>
  </required_header>
  <id_info>
    <org_study_id>MORAB-003-J081-102</org_study_id>
    <nct_id>NCT01049061</nct_id>
  </id_info>
  <brief_title>A Study of MORAb-003 in Patients With Solid Tumor</brief_title>
  <official_title>A Phase 1 Study of MORAb-003 in Patients With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      MORAb-003 is intravenously administered to Japanese patients with folate receptor-alpha
      expressing solid tumor once a week for 4 weeks as 1 cycle in order to investigate
      dose-limiting toxicity and estimate maximum tolerated dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate dose-limiting toxicity and estimate maximum tolerated dose.</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Patients With a Folate-receptor Alpha Expressing Solid Tumor Who Are Not Responsive or Resistant to Standard Therapy and Have no Other Appropriate Treatment.</condition>
  <arm_group>
    <arm_group_label>MORAb-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MORAb-003</intervention_name>
    <description>MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose</description>
    <arm_group_label>MORAb-003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria;

          1. Japanese male and female aged &gt;or=20 to &lt;80 years at obtaining informed consent

          2. Patient with histologically or cytologically diagnosed solid tumor

          3. Patient who is FRα-positive confirmed by immunohistochemistry (IHC) (except for
             ovarian cancer that FRα-positive is frequently reported)

          4. Patients with a folate-receptor alpha expressing solid tumor who are not responsive or
             resistant to standard therapy and have no other appropriate treatment

          5. Performance Status (PS) is 0 to 1 by Eastern Cooperative Oncology Group（ECOG）criteria

        Exclusion criteria

          1. Brain metastasis presenting clinical symptoms or requiring medical treatment

          2. Serious and systemic infection requiring medical treatment

          3. History of hypersensitivity to protein formulations including monoclonal antibody

          4. With other active malignancy (except for carcinoma in situ)

          5. With a large volume of pleural effusion or ascites requiring drainage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chifumi Kitamura</last_name>
    <role>Study Director</role>
    <affiliation>JAC PCU Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hidaka-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>FRα</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

